CCND1 and prostate adenocarcinoma: For example, in advanced PRAD in particular, CCND1 overexpression is associated with resistance to androgen deprivation therapy (ADT) (59, 62), a common therapeutic challenge, and targeting circFOXK2 and CCND1 could therefore be a promising strategy to overcome such resistance.